Description
Description: This assay employs a two-site sandwich ELISA to quantitate YIPF3 in samples. An antibody specific for YIPF3 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any YIPF3 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for YIPF3 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of YIPF3 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Overview: KLIP1 contains an N-terminal signal sequence, followed by an extracellular domain, 5 transmembrane regions, and a cytoplasmic C-terminal sequence. It also has 3 potential protein kinase C phosphorylation sites. KLIP1 expression closely correlated with hematopoietic activity in both intra- and extra-embryonic hematopoietic sites. In day 30/32 human embryo
sections, KLIP1 protein expression was restricted to circulating hematopoietic cells at hematopoiesis sites. Membrane KLIP1 was expressed by fetal and adult GPA-positive erythroblasts, the fetal liver CD34-positive subset, fetal spleen, and adult bone marrow CD56 (NCAM1)-positive natural killer and CD19-positive B cells. Among mature blood cells, surface KLIP1 expression was restricted to CD56-positive natural killer cells